These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 26246238)
1. Differences in utility scores obtained through Brazilian and UK value sets: a cross-sectional study. Takemoto ML; Lopes da Silva N; Ribeiro-Pereira AC; Schilithz AO; Suzuki C Health Qual Life Outcomes; 2015 Aug; 13():119. PubMed ID: 26246238 [TBL] [Abstract][Full Text] [Related]
2. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446 [TBL] [Abstract][Full Text] [Related]
3. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study. da Silva NL; Takemoto MLS; Damasceno A; Fragoso YD; Finkelsztejn A; Becker J; Gonçalves MVM; Tilbery C; de Oliveira EML; Callegaro D; Boulos FC BMC Health Serv Res; 2016 Mar; 16():102. PubMed ID: 27009599 [TBL] [Abstract][Full Text] [Related]
4. Comparison of FACT- and EQ-5D-based utility scores in cancer. Pickard AS; Ray S; Ganguli A; Cella D Value Health; 2012; 15(2):305-11. PubMed ID: 22433762 [TBL] [Abstract][Full Text] [Related]
5. Association between Disability, Cognition, Fatigue, EQ-5D-3L Domains, and Utilities Estimated with Different Western European Value Sets in Patients with Multiple Sclerosis. Eriksson J; Kobelt G; Gannedahl M; Berg J Value Health; 2019 Feb; 22(2):231-238. PubMed ID: 30711069 [TBL] [Abstract][Full Text] [Related]
6. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis. Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061 [TBL] [Abstract][Full Text] [Related]
7. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Orme M; Kerrigan J; Tyas D; Russell N; Nixon R Value Health; 2007; 10(1):54-60. PubMed ID: 17261116 [TBL] [Abstract][Full Text] [Related]
8. Using the Fatigue Severity Scale to inform healthcare decision-making in multiple sclerosis: mapping to three quality-adjusted life-year measures (EQ-5D-3L, SF-6D, MSIS-8D). Goodwin E; Hawton A; Green C Health Qual Life Outcomes; 2019 Aug; 17(1):136. PubMed ID: 31382960 [TBL] [Abstract][Full Text] [Related]
9. EQ-5D Brazilian population norms. Santos M; Monteiro AL; Santos B Health Qual Life Outcomes; 2021 Jun; 19(1):162. PubMed ID: 34112207 [TBL] [Abstract][Full Text] [Related]
10. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Petrou S; Hockley C Health Econ; 2005 Nov; 14(11):1169-89. PubMed ID: 15942981 [TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life and utilities among Lebanese patients with Multiple Sclerosis: A cross-sectional study. Dahham J; Hiligsmann M; Kremer I; Khoury SJ; Darwish H; Hosseini H; Hallit S; Evers S; Rizk R Mult Scler Relat Disord; 2024 Jun; 86():105635. PubMed ID: 38640585 [TBL] [Abstract][Full Text] [Related]
12. Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease. Bae E; Choi SE; Lee H; Shin G; Kang D BMC Pulm Med; 2020 Mar; 20(1):73. PubMed ID: 32293387 [TBL] [Abstract][Full Text] [Related]
13. Validation and comparison of EuroQol and short form 6D in chronic prostatitis patients. Zhao FL; Yue M; Yang H; Wang T; Wu JH; Li SC Value Health; 2010 Aug; 13(5):649-56. PubMed ID: 20412540 [TBL] [Abstract][Full Text] [Related]
14. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis. Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K; Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665 [TBL] [Abstract][Full Text] [Related]
15. Predicting the EuroQol Group's EQ-5D index from CDC's "Healthy Days" in a US sample. Jia H; Zack MM; Moriarty DG; Fryback DG Med Decis Making; 2011; 31(1):174-85. PubMed ID: 20375418 [TBL] [Abstract][Full Text] [Related]
16. Health Utilities for Multiple Sclerosis. Hawton A; Green C Value Health; 2016 Jun; 19(4):460-8. PubMed ID: 27325338 [TBL] [Abstract][Full Text] [Related]
17. Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5D. Fogarty E; Walsh C; Adams R; McGuigan C; Barry M; Tubridy N Mult Scler; 2013 Aug; 19(9):1190-6. PubMed ID: 23401128 [TBL] [Abstract][Full Text] [Related]
18. Assessment of health state in patients with tinnitus: a comparison of the EQ-5D and HUI mark III. Maes IH; Joore MA; Cima RF; Vlaeyen JW; Anteunis LJ Ear Hear; 2011; 32(4):428-35. PubMed ID: 21221004 [TBL] [Abstract][Full Text] [Related]
19. Validity and reliability of Persian version of Modified Fatigue Impact Scale (MFIS) questionnaire in Iranian patients with multiple sclerosis. Ghajarzadeh M; Jalilian R; Eskandari G; Ali Sahraian M; Reza Azimi A Disabil Rehabil; 2013 Aug; 35(18):1509-12. PubMed ID: 23237227 [TBL] [Abstract][Full Text] [Related]
20. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. Pickard AS; Gooderham M; Hartz S; Nicolay C J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]